

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

PerCP anti-human CD3

RRID:AB_893298

Type: Antibody

Proper Citation

BioLegend Cat# 300428, RRID:AB_893298

Antibody Information

URL: http://antibodyregistry.org/AB_893298

Proper Citation: BioLegend Cat# 300428, RRID:AB_893298

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_893298

Vendor: BioLegend

Catalog Number: 300428

Alternative Catalog Numbers: 300427

Record Creation Time: 20250819T235649+0000

Record Last Update: 20250820T065428+0000

Ratings and Alerts

No rating or validation information has been found for PerCP anti-human CD3.

No alerts have been found for PerCP anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Reilly RB, et al. (2024) An altered natural killer cell immunophenotype characterizes clinically severe pediatric RSV infection. *Science translational medicine*, 16(768), eado6606.

Reincke SM, et al. (2023) Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. *Cell*, 186(23), 5084.

Tamura T, et al. (2023) Single-cell transcriptomics reveal a hyperacute cytokine and immune checkpoint axis after cardiac arrest in patients with poor neurological outcome. *Med (New York, N.Y.)*, 4(7), 432.

Preechanukul A, et al. (2023) Identification and function of a novel human memory-like NK cell population expressing CD160 in melioidosis. *iScience*, 26(8), 107234.

Moore SC, et al. (2023) Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. *Med (New York, N.Y.)*, 4(3), 191.

Wenthe J, et al. (2023) Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. *Journal of translational medicine*, 21(1), 506.

Tan ZC, et al. (2023) Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates. *Cell reports*, 42(7), 112734.

Terahara K, et al. (2022) SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype. *iScience*, 25(9), 104959.

Jaiswal A, et al. (2022) An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. *Cancer cell*, 40(5), 524.

Wenthe J, et al. (2021) Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. *Cancer immunology, immunotherapy : CII*, 70(10), 2851.

Ahmed R, et al. (2019) A Public BCR Present in a Unique Dual-Receptor-Expressing Lymphocyte from Type 1 Diabetes Patients Encodes a Potent T Cell Autoantigen. *Cell*, 177(6), 1583.

Leng T, et al. (2019) TCR and Inflammatory Signals Tune Human MAIT Cells to Exert Specific Tissue Repair and Effector Functions. *Cell reports*, 28(12), 3077.

Wang W, et al. (2019) Type I Interferon Therapy Limits CNS Autoimmunity by Inhibiting CXCR3-Mediated Trafficking of Pathogenic Effector T Cells. *Cell reports*, 28(2), 486.